Iambic Therapeutics surges 8%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Iambic Therapeutics (IAM.US) surged more than 8% during regular trading to $14.48.

The stock is down 12.25% from its first-day open and sits 50.83% above its 52-week low of US$9.600.

The Nasdaq Composite is down 1.28% over the past five sessions and up 7.77% year to date.

Iambic presented updated Phase 1/1b clinical trial results for its HER2 inhibitor IAM1363 at the European Society for Medical Oncology congress, showing durable responses and good tolerability in heavily pretreated patients with HER2-mutated advanced cancer.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Recommended Readings